Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2024 | The impact of inotuzumab bridging on the outcomes of patients with R/R B-ALL treated with obe-cel

Jae Park • 16 Dec 2024
ASH 2024
Acute Lymphoblastic Leukemia Leukemia Antibodies CAR-T Inotuzumab ozogamicin Obecabtagene autoleucel
FELIX

Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the impact of inotuzumab ozogamicin bridging therapy on CAR T-cell expansion and outcomes in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel (obe-cel) in the Phase Ib/II FELIX study (NCT04404660). Dr Park highlights that inotuzumab was effective in reducing disease burden without significantly affecting CAR T-cell expansion. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jae Park

The durability of responses with CAR T-cell therapy in ALL and predictors of long-term remission 3:30
The durability of responses with CAR T-cell therapy in ALL and predictors of long-term remission
Jae Park • 18 Jun 2025
Treating ALL in community settings without access to sophisticated MRD testing 2:47
Treating ALL in community settings without access to sophisticated MRD testing
Jae Park • 18 Jun 2025
The role of MRD in risk stratification and treatment decisions for adult ALL 3:30
The role of MRD in risk stratification and treatment decisions for adult ALL
Jae Park • 18 Jun 2025
Long-term data on obe-cel and its potential as a definitive treatment for adult R/R B-ALL 4:51
Long-term data on obe-cel and its potential as a definitive treatment for adult R/R B-ALL
Jae Park • 18 Jun 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals